Indonesia vs Malawi: Average cost of multi drug-resistant tuberculosis treatment
Indonesia
1,138 constant 2022 US$
in 2024
Malawi
1,246 constant 2022 US$
in 2024
Indonesia rank
41st
Malawi rank
38th
Average cost of multi drug-resistant tuberculosis treatment over time
- Indonesia
- Malawi
How they compare
Malawi currently reports 1,246 constant 2022 US$ against 1,138 constant 2022 US$ in Indonesia, a difference of 108 constant 2022 US$.
That makes Malawi's figure about 1.1 times Indonesia's.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Malawi ahead.
Indonesia ranks 41st and Malawi ranks 38th of 92 countries.
Malawi has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Indonesia | Malawi | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,463 constant 2022 US$ | 2,631 constant 2022 US$ | 1,168 constant 2022 US$ | Malawi |
| 2020s | 1,466 constant 2022 US$ | 1,785 constant 2022 US$ | 319 constant 2022 US$ | Malawi |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Indonesia or Malawi?
- Malawi, at 1,246 constant 2022 US$ against 1,138 constant 2022 US$ in Indonesia as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Indonesia and Malawi?
- 108 constant 2022 US$, with Malawi ahead.
- How many years of comparable data are there for Indonesia and Malawi?
- 8 years are reported by both, from 2017 to 2024.
- How do Indonesia and Malawi rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Indonesia ranks 41st and Malawi ranks 38th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.